← Back to Search

Vitamin Supplement

Nicotinamide Riboside Malate for Vascular Stiffness (NRM Trial)

N/A
Recruiting
Led By Ryan Hurt, MD
Research Sponsored by Mayo Clinic
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline to end of study at 12 weeks

Summary

"This trial aims to investigate how a nicotinamide riboside supplement can impact the heart health of healthy adults."

Who is the study for?
This trial is for healthy adults aged 40-60 who are not pregnant, nursing, or trying to conceive. Participants must understand and agree to the study's procedures without any chronic diseases, unstable medical conditions, severe obesity, or recent use of certain natural health products.
What is being tested?
The trial is testing the effects of a supplement called Nicotinamide Riboside Malate on cardiovascular health in comparison with a placebo. The goal is to see if this supplement can improve vascular function in healthy individuals.
What are the potential side effects?
While specific side effects are not listed for this trial, potential risks may include allergic reactions to ingredients in the supplement and possible unknown impacts on liver or kidney function.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline to end of study at 12 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline to end of study at 12 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Number of Participants with Reduced Endothelial Stiffness

Trial Design

3Treatment groups
Active Control
Placebo Group
Group I: 830 mg Nicotinamide and PlaceboActive Control2 Interventions
830 mg Nicotinamide supplement capsule and 1 identical Placebo capsule twice a day for 12 weeks
Group II: 1660 mg NicotinamideActive Control1 Intervention
1660 mg Nicotinamide supplement; 2 of the 830 mg capsules twice a day for 12 weeks
Group III: PlaceboPlacebo Group1 Intervention
2 identical Placebo capsules twice a day for 12 weeks

Find a Location

Who is running the clinical trial?

Mayo ClinicLead Sponsor
3,344 Previous Clinical Trials
3,062,203 Total Patients Enrolled
Ryan Hurt, MDPrincipal InvestigatorMayo Clinic
Ryan Hurt, MD, PhDPrincipal InvestigatorMayo Clinic
4 Previous Clinical Trials
147 Total Patients Enrolled
~133 spots leftby Feb 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top